"A startup can be just as big a success as a Leibniz Prize!"
Matthias Tschöp, CEO of Helmholtz Munich, talks about translating scientific discoveries into clinical practice, about ambitious targets, and about ideas he acquired during his time in the USA.
Dermagnostix receives EIC funding of 2,5 million euros
The medical technology company Dermagnostix GmbH is a joint spin-off of Helmholtz Munich, the Technical University (TU) Munich and Hahn-Schickard. Its goal: to redefine molecular diagnostics in dermatology. Dermagnostix has now qualified as one of 30…
Researchers at Helmholtz Munich are working toward a world without diabetes. They are not doing so alone, but with a network of organizations, hospitals, and pharmaceutical companies. Their goal is to use experts’ knowledge to create something new:…
New Drug Candidate Developed to Treat Type 2 Diabetes
A team of researchers from Helmholtz Munich, the German Center for Diabetes Research (DZD) and Novo Nordisk have developed a new hormone combination for the future treatment of type 2 diabetes. The scientists have combined the blood sugar-reducing…
Transfer,
New Research Findings,
Bioengineering,
IBMI,
Under the Skin: Better Treatment of Psoriasis by Scanning Light and Sound
A clinical study confirms the success of a novel technology developed by Helmholtz Munich and the Technical University of Munich (TUM) for the evaluation of the treatment of psoriasis. With the new method, doctors can look deeper into the skin of…
Epstein-Barr Virus: Helmholtz Munich and DZIF Are Working on a Vaccine
The Epstein-Barr virus (EBV) has been known for some time to play a part in a range of diseases. A current US study has now shown a close link between EBV and multiple sclerosis. Scientists at Helmholtz Munich and DZIF are already working on…
